CMS Finalizes Changes to “Best Price” Rules in Bid to Ease Value-Based Deals with Drug Makers
- January 08, 2021
The Centers for Medicare & Medicaid Services (CMS) issued a final rule (85 Fed Reg. 87000) aimed at paving the way for state Medicaid programs and private payers to enter value-based deals with drug manufacturers that base payment on a treatment’s effectiveness.
You must be logged in to access this content.